Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16111 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yiqin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Key Laboratory of National Health Commission, and Key Laboratory of Nephrology, Guangdong Province, Guangzhou, China, National Natural Science Foundation of China-Guangdong Joint Fund, National Key Research and Development Project of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The ACCORD trial showed that intensive glucose‐lowering therapy has a limited impact on renal function decline. We aimed to identify subgroups in the ACCORD population that might derive renal benefits from intensive glucose‐lowering therapy. Materials and Methods The primary renal outcome included a ≥50% decline in baseline estimated glomerular filtration rate or end‐stage renal disease (ESRD). Using the causal tree model, we employed internal cross‐validation to identify five pivotal variables influencing the renal efficacy of intensive glycaemic control. These variables were integrated into the model‐based recursive partitioning approach, yielding a visualizable tree model that depicted benefitting subgroups.
Results
Node 4, characterized by no cardiovascular history, systolic blood pressure (SBP) ≤142.67 mm Hg, and triglycerides ≤172 mg/dL, showed significantly reduced hazards of the composite renal outcome (fully adjusted hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.49–0.89; p = 0.006) and doubling of serum creatinine (fully adjusted HR 0.59, 95% CI 0.36–0.98; p = 0.041). Node 7 (no cardiovascular history and SBP 142.67–154 mm Hg) showed reduced hazards of the primary renal outcome (fully adjusted HR 0.67, 95% CI 0.49–0.93; p = 0.016) and ESRD (fully adjusted HR 0.35, 95% CI 0.17–0.74; p = 0.0057). Encouragingly, neither node 4 nor node 7 displayed elevated cardiovascular risk or hypoglycaemic events.
Conclusions
Through innovative machine learning, we identified ACCORD subgroups benefitting significantly from intensive glycaemic therapy for renal outcomes, without increased cardiovascular or hypoglycaemic risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China.
ORCID-Profile: Wei Chen
Förderung
- Key Laboratory of National Health Commission, and Key Laboratory of Nephrology, Guangdong Province, Guangzhou, China
- National Natural Science Foundation of China-Guangdong Joint Fund
- National Key Research and Development Project of China
- 5010 Clinical Program of Sun Yat-Sen University
- Guangzhou Science and Technology Project
- Natural Science Foundation of Guangdong Province, China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Wang, Y., Wen, Q., Lu, Y., Yang, J., Huang, N., & Chen, W. (2025). Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16111
Vancouver
Wang Y, Wen Q, Lu Y, Yang J, Huang N, Chen W. Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16111
BibTeX
@article{Wang2025,
author = {Wang, Yiqin and Wen, Qiong and Lu, Yuewen and Yang, Jiayi and Huang, Naya and Chen, Wei},
title = {Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16111}
}
EUVIMED